Elanco Animal Health (NYSE:ELAN) Rating Lowered to “Hold” at Jefferies Financial Group

Posted by Brenda Bartman on Oct 20th, 2026

Elanco Animal Health (NYSE:ELAN – Get Free Report) was downgraded by investment analysts at Jefferies Financial Group from a “buy” rating to a “hold” rating in a report released on Tuesday, MarketBeat Ratings reports. They currently have a $24.00 target price on the stock, down from their prior target price of $31.00. Jefferies Financial Group’s price objective would suggest a potential upside of 5.81% from the stock’s previous close.

A number of other equities analysts have also commented on ELAN. The Goldman Sachs Group initiated coverage on shares of Elanco Animal Health in a research report on Friday, October 16th. They issued a “buy” rating and a $32.00 price target on the stock. Weiss Ratings upgraded shares of Elanco Animal Health from a “sell (d)” rating to a “sell (d+)” rating in a research note on Friday, September 4th. Morgan Stanley upped their price objective on shares of Elanco Animal Health from $23.00 to $26.00 and gave the stock an “equal weight” rating in a report on Wednesday, July 22nd. Piper Sandler reaffirmed an “overweight” rating on shares of Elanco Animal Health in a report on Monday, June 29th. Finally, KeyCorp reiterated an “overweight” rating on shares of Elanco Animal Health in a research note on Wednesday, September 30th. One analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $29.42.

View Our Latest Research Report on ELAN

Elanco Animal Health Stock Performance

ELAN opened at $22.68 on Tuesday. The company has a market cap of $11.33 billion, a PE ratio of -55.32, a price-to-earnings-growth ratio of 2.08 and a beta of 1.70. The stock has a 50-day moving average of $23.24 and a 200-day moving average of $23.57. Elanco Animal Health has a 52-week low of $19.40 and a 52-week high of $27.98. The company has a debt-to-equity ratio of 0.58, a quick ratio of 1.10 and a current ratio of 2.05.

Elanco Animal Health (NYSE:ELAN – Get Free Report) last issued its quarterly earnings data on Wednesday, August 5th. The company reported $0.34 earnings per share for the quarter, beating analysts’ consensus estimates of $0.27 by $0.07. Elanco Animal Health had a positive return on equity of 8.13% and a negative net margin of 3.96%. The business had revenue of $1.37 billion for the quarter, compared to the consensus estimate of $1.31 billion. During the same period last year, the business earned $0.26 EPS. The firm’s revenue was up 10.2% compared to the same quarter last year. Elanco Animal Health has set its Q3 2026 guidance at 0.190-0.220 EPS and its FY 2026 guidance at 1.100-1.160 EPS. As a group, equities research analysts forecast that Elanco Animal Health will post 1.13 earnings per share for the current fiscal year.

Insider Buying and Selling at Elanco Animal Health

In related news, Director Lawrence Kurzius bought 40,000 shares of the company’s stock in a transaction that occurred on Thursday, August 20th. The shares were acquired at an average price of $23.40 per share, with a total value of $936,000.00. Following the completion of the transaction, the director owned 188,647 shares of the company’s stock, valued at $4,414,339.80. The trade was a 26.91% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Michael Harrington bought 5,000 shares of the business’s stock in a transaction that occurred on Wednesday, August 12th. The shares were bought at an average price of $21.82 per share, with a total value of $109,100.00. Following the completion of the purchase, the director owned 131,451 shares in the company, valued at approximately $2,868,260.82. The trade was a 3.95% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders have purchased a total of 63,198 shares of company stock valued at $1,473,109 in the last three months. 1.14% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Anchor Investment Management LLC bought a new position in Elanco Animal Health during the 2nd quarter valued at about $29,000. Integrated Wealth Concepts LLC acquired a new position in Elanco Animal Health in the second quarter valued at about $35,000. Mitsubishi UFJ Asset Management Co. Ltd. bought a new stake in Elanco Animal Health during the second quarter worth about $38,000. Bessemer Group Inc. grew its stake in Elanco Animal Health by 33.2% during the first quarter. Bessemer Group Inc. now owns 2,105 shares of the company’s stock worth $50,000 after buying an additional 525 shares during the last quarter. Finally, Farther Finance Advisors LLC grew its stake in Elanco Animal Health by 12.5% during the third quarter. Farther Finance Advisors LLC now owns 4,184 shares of the company’s stock worth $94,000 after buying an additional 464 shares during the last quarter. Institutional investors own 97.48% of the company’s stock.

About Elanco Animal Health

(Get Free Report)

Elanco Animal Health Incorporated is a global animal health company that develops, manufactures and markets products for pets and food-producing animals. Its portfolio is designed to help prevent and treat disease, control parasites and support the health and productivity of animals.

The company’s products include vaccines, parasiticides, antibiotics, nutritional supplements and other prescription and over-the-counter therapies. Its companion animal offerings address conditions such as flea and tick infestations, internal parasites, osteoarthritis and dermatological disorders, while its farm animal products support the health of cattle, poultry, swine and aquaculture species.

Elanco serves customers in markets around the world through relationships with veterinarians, animal owners, livestock producers, retailers and distributors.